Related Experiment Video
Updated: Nov 17, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.1K
Microtubule Inhibitors and Cardiotoxicity
Amogh M Joshi1, George S Prousi2, Christopher Bianco3
1Department of Internal Medicine, Lehigh Valley Health Network, Allentown, PA, USA.
Current Oncology Reports
|February 14, 2021
Summary
Microtubule inhibitor agents used in cancer therapy can cause heart problems like arrhythmias and heart failure. Further research is needed to develop guidelines for managing these cardiovascular risks in patients.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Cancer and heart disease are leading causes of mortality in the USA.
- Chemotherapeutic agents are increasingly used for cancer treatment.
- Cardiovascular complications are known adverse effects of some cancer therapies.
Purpose of the Study:
- To review the cardiovascular effects of microtubule inhibitor (MTI) agents.
- To understand the mechanisms of MTI-induced cardiotoxicity.
- To identify current gaps in guidelines for managing MTI-related cardiovascular complications.
Main Methods:
- Literature review focusing on microtubule inhibitors and cardiovascular effects.
- Analysis of studies detailing cardiotoxicity associated with MTI therapy.
Main Results:
- Microtubule inhibitor agents are associated with various cardiotoxicities, including heart failure, myocardial ischemia, and conduction abnormalities.
- Brady- and tachyarrhythmias are the most frequently reported cardiotoxicities.
- Concurrent use of anthracyclines with MTIs may elevate cardiotoxicity risk.
Conclusions:
- While fatal cardiotoxicities are rare, MTIs pose significant cardiovascular risks.
- There is a lack of established guidelines for preventing and mitigating cardiovascular complications in patients receiving MTI therapy.
- Further research is warranted to develop evidence-based strategies for managing MTI-induced cardiotoxicity.
Keywords:
ArrhythmiaCardio-oncologyCardiotoxicityEndothelial dysfunctionHeart failureMitotic inhibitorsMore Related Videos
Related Concept Videos
01:15Drugs that Stabilize Microtubules
2.3K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
01:10Drugs that Destabilize Microtubules
2.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
01:26Heart Failure Drugs: Inotropic Agents
931
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
931
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
666
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666
01:46Electron Transport Chain: Complex I and II
16.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
16.9K
01:45Destabilization of Microtubules
3.2K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.2K